Trevogrumab

Human clinical Muscle & Bone Health 3 sources

Trevogrumab (also known as REGN1033) is a fully human monoclonal antibody designed to specifically bind and neutralize myostatin, a natural protein that inhibits muscle growth. Research has focused on its potential to treat muscle wasting conditions, sarcopenia, and muscular dystrophies by promoting increases in lean muscle mass.

01Dosing reference

Amount

3 mg/kg to 10 mg/kg (clinical trial dosing)

Frequency

Every 2 to 4 weeks via SubQ or IV injection

Cycle

12-24 weeks in clinical trial settings

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Myostatin Binding

Trevogrumab specifically binds to the myostatin (GDF-8) ligand in the extracellular space.

Receptor Blockade

By neutralizing myostatin, it prevents the ligand from binding to and activating the ActRIIB receptor on muscle cells.

Muscle Hypertrophy

The removal of myostatin's inhibitory signaling pathway allows for increased muscle protein synthesis and subsequent muscle growth.

03Human evidence

Increased lean body mass in healthy older adults and patients with sarcopenia.

Phase 2 clinical trials demonstrated dose-dependent increases in appendicular lean mass, though functional strength improvements were variable.

Evaluated for safety and efficacy in muscular dystrophy.

Clinical trials in patients with facioscapulohumeral muscular dystrophy (FSHD) showed it was generally well-tolerated, but translating muscle mass gains into significant functional improvements remained challenging.

04Preclinical evidence

Preservation of muscle mass in atrophy models.

In murine models of immobilization-induced muscle atrophy, treatment with the antibody significantly prevented muscle loss and improved recovery.

Enhanced skeletal muscle hypertrophy.

Studies in healthy mice and non-human primates showed significant increases in skeletal muscle mass and cross-sectional area without adverse effects on cardiac muscle.

05What is known vs. unknown

Reasonably established

Trevogrumab is a monoclonal antibody, not a traditional short-chain peptide.
It acts as a direct myostatin inhibitor by binding to the GDF-8 ligand.
Clinical trials have consistently shown its ability to increase lean muscle mass.
It has been investigated primarily for age-related sarcopenia and specific muscular dystrophies.

Unknowns & limits

The translation of increased muscle mass into meaningful functional strength and mobility improvements remains inconsistent in human trials.
Long-term safety profiles, particularly concerning tendon adaptation to rapid muscle growth, are not fully established.
Optimal dosing strategies for chronic muscle wasting conditions require further investigation.

06Safety & regulatory context

Regulatory statusTrevogrumab is an investigational drug and is not FDA-approved for any medical condition. In clinical trials, it has generally been well-tolerated with a manageable safety profile. Reported adverse events have included mild injection site reactions, nasopharyngitis, and musculoskeletal pain. Because it promotes muscle growth, there is a theoretical risk of muscle-tendon imbalance if connective tissues do not adapt at the same rate as muscle tissue. It remains strictly for research and clinical trial use.

07Compared with Bimagrumab

Trevogrumab vs. Bimagrumab

Key difference

Trevogrumab binds directly to the myostatin ligand to neutralize it, whereas Bimagrumab binds to the ActRIIB receptor, blocking multiple ligands including myostatin and activin A.

When researchers discuss each

Researchers discuss Trevogrumab when seeking highly specific myostatin inhibition with potentially fewer off-target effects, while Bimagrumab is explored when a broader, more potent anabolic response is desired despite a different side effect profile.

08Glossary

Myostatin (GDF-8)

A protein produced by muscle cells that acts to inhibit muscle growth, ensuring muscles do not grow too large.

Monoclonal Antibody

A laboratory-produced molecule engineered to serve as a substitute antibody that can specifically bind to a target substance in the body.

Sarcopenia

The age-related progressive loss of skeletal muscle mass, strength, and function.

ActRIIB Receptor

A receptor on the surface of muscle cells that myostatin binds to in order to transmit its growth-inhibiting signal.

09Knowledge check

Q1What is the primary mechanism of action for Trevogrumab?

Q2Which of the following is a primary challenge observed in Trevogrumab clinical trials?

Q3When interpreting phase 2 results that showed dose-dependent increases in appendicular lean mass with Trevogrumab, which conclusion aligns best with the dossier's evidence and limitations?

Q4According to the dossier's comparison with Bimagrumab, which rationale best explains when researchers might choose Trevogrumab?

Q5Which statement best reflects Trevogrumab's safety and regulatory context as described in the dossier?

10Sources

ClinicalTrials.gov Safety, Tolerability, and Efficacy of REGN1033 in Sarcopenia
PubMed Myostatin inhibition as a therapeutic strategy for muscle wasting
ClinicalTrials.gov A Phase 2 Study of Trevogrumab in Patients With Myopathy

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health

Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

GDF-8 Myostatin Inhibitor

Muscle & Bone Health

Early human

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

ACE-031

Muscle & Bone Health

Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.